Results 21 to 30 of about 24,646 (191)

Management of acute coronary syndromes with fondaparinux

Vascular Health and Risk Management, 2007
Harm Wienbergen, Uwe ZeymerHerzzentrum Ludwigshafen, Medizinische Klinik B, GermanyAbstract: Fondaparinux is the first selective inhibitor of the coagulation factor Xa which is commercially avaliable for clinical use.
Harm Wienbergen, Uwe Zeymer
doaj   +1 more source

Failure of Fondaparinux in Autoimmune Heparin-Induced Thrombocytopenia [PDF]

TH Open, 2020
Heparin-induced thrombocytopenia (HIT) is an immune adverse reaction to heparin that is associated with life-threatening thrombotic complications.
Michelangelo Sartori, Benilde Cosmi
doaj   +2 more sources

Advances in Chemical Synthesis of Fondaparinux

Journal of Chemistry, 2019
Fondaparinux (trade name Arixtra) is a safe and efficacious anticoagulant, and it is chemically related to low-molecular-weight heparins such as enoxaparin. Fondaparinux is a synthetic pentasaccharide, and its synthesis is difficult and expensive.
Yili Ding, Chamakura V. N. S. Vara Prasad, Bingyun Wang   +2 more
doaj   +2 more sources

Efficacy and safety of fondaparinux in elective total hip arthroplasty and hip fracture surgery: a systematic review and meta-analysis [PDF]

Journal of Orthopaedic Surgery and Research
Background As life expectancy increases, the incidence of hip fractures and the demand for total hip arthroplasties (THA) are expected to rise. This demographic shift poses significant challenges, particularly in managing post-operative complications ...
Gonzalo Mariscal, Francisco José Tarazona-Santabalbina, Oliver Marin-Peña, Erika Rotavista, Sara Arroyo Martín, María Estrella Fernández de Sevilla, Jesús Gómez-Vallejo   +6 more
doaj   +2 more sources

Fondaparinux vs warfarin for the treatment of unsuspected pulmonary embolism in cancer patients

Drug Design, Development and Therapy, 2016
Bruno Amato,1,2,* Rita Compagna,1,2,* Aldo Rocca,2 Tommaso Bianco,2 Marco Milone,2 Luigi Sivero,2 Gabriele Vigliotti,2 Maurizio Amato,2 Michele Danzi,2 Giovanni Aprea,2 Luca Gallelli,3,* Stefano de Franciscis,1,4,* Raffaele Serra1,4,* 1Interuniversity ...
Amato B, Compagna R, Rocca A, Bianco T, Milone M, Sivero L, Vigliotti G, Amato M, Danzi M, Aprea G, Gallelli L, de Franciscis S, Serra R   +12 more
doaj   +2 more sources

Maculopathy after long-term use of fondaparinux, a heparin mimetic and heparanase inhibitor [PDF]

American Journal of Ophthalmology Case Reports
Purpose: To report maculopathy associated with the long-term use of fondaparinux, a heparin mimetic and inhibitor of the extracellular matrix enzyme, heparanase.
Benjamin R. Lin, Erick Rivera-Grana, Wenting Zhou, Mark Barakat, Philip J. Rosenfeld, Janet L. Davis   +5 more
doaj   +2 more sources

Use of fondaparinux in patients with heparin-induced thrombocytopenia on veno-venous extracorporeal membrane oxygenation: A three-patient case series report

Frontiers in Medicine, 2023
Heparin-induced thrombocytopenia is a life-threatening immune-mediated complication of unfractionated heparin therapy. Fondaparinux is a therapeutic alternative, but it has limited evidence for its use in patients on extracorporeal membrane oxygenation ...
Jitka Rychlíčková, Jitka Rychlíčková, Jitka Rychlíčková, Vladimír Šrámek, Vladimír Šrámek, Pavel Suk, Pavel Suk   +6 more
doaj   +1 more source

Study on the safety and effectiveness of low-dose vs. regular-dose fondaparinux in preventing venous thromboembolism prophylaxis following total knee arthroplasty

Frontiers in Cardiovascular Medicine, 2023
BackgroundThis study aims to evaluate the effectiveness and safety of low-dose (1.5 mg) fondaparinux for venous thromboembolism (VTE) prophylaxis in patients post-total knee arthroplasty (TKA).MethodsWe retrospectively identified 314 patients who carried
Ping-bo Chen, Jing Wang, Lei Wang, Shou-liang Xiong, Chao Wang, Xin Yang, Cong-ming Li, Qiang Wang, Yin-chang Zhang   +8 more
doaj   +1 more source

Fondaparinux cross-reactivity in heparin-induced thrombocytopenia successfully treated with high-dose intravenous immunoglobulin and rivaroxaban

Platelets, 2020
HIT, a prothrombotic disorder caused by heparin-dependent antibodies, is often treated with fondaparinux, usually with good outcomes. A 70-year-old female developed severe HIT (platelet count, 25 × 109/L) post-glioblastoma resection during heparin ...
Farheen Manji, Theodore E. Warkentin, Jo-Ann I. Sheppard, Adrienne Lee   +3 more
doaj   +1 more source

Retrospective Analysis of Fondaparinux and Low-Molecular-Weight Heparin in the Treatment of Women With Recurrent Spontaneous Abortion

Frontiers in Endocrinology, 2021
BackgroundTo compare the clinical efficacy of fondaparinux and LMWH and provide clinical evidence for the effectiveness of fondaparinux in the treatment of recurrent spontaneous abortion caused by PTS.MethodsA retrospective analysis was conducted for 120
Long Zhao, Shuqin Bi, Jinhua Fu, Lijuan Qi, Lin Li, Yinghui Fu   +5 more
doaj   +1 more source